Driven by recent clinical breakthroughs and technological progress, 30 antibody–drug conjugates against over 24 targets are now in trials for blood cancers and solid tumours.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Cancer Cell International Open Access 13 August 2022
-
Natural Products in Cancer Therapy: Past, Present and Future
Natural Products and Bioprospecting Open Access 03 January 2021
-
New insight on the structural features of the cytotoxic auristatins MMAE and MMAF revealed by combined NMR spectroscopy and quantum chemical modelling
Scientific Reports Open Access 21 November 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Change history
08 May 2013
PDB has been corrected to PBD, and the text has been updated to clarify Stuart Lutzker's affiliation. This has now been corrected in the HTML and PDF versions of the article.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Mullard, A. Maturing antibody–drug conjugate pipeline hits 30. Nat Rev Drug Discov 12, 329–332 (2013). https://doi.org/10.1038/nrd4009
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4009
This article is cited by
-
Advances in antibody-based therapy in oncology
Nature Cancer (2023)
-
Potential of antibody–drug conjugates (ADCs) for cancer therapy
Cancer Cell International (2022)
-
Natural Products in Cancer Therapy: Past, Present and Future
Natural Products and Bioprospecting (2021)
-
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
Protein & Cell (2018)
-
Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b
BMC Cancer (2017)